Corvidia Therapeutics Inc., a clinical stage biotechnology company, announced today the initiation of patient screening for a Phase 2b dose-finding study of ziltivekimab. Previously known as COR-001, ziltivekimab is a proprietary anti-interleukin-6 ligand monoclonal antibody (anti-IL6 mAb), targeting residual inflammatory cardiovascular risk in patients living with advanced chronic kidney disease (CKD).
{iframe}https://www.businesswire.com/news/home/20190613005101/en/Corvidia-Therapeutics-Initiates-Phase-2b-Dose-Finding-Study{/iframe}